Otonomy Inc., of San Diego, completed enrollment in a phase II study evaluating Auripro, its sustained-exposure formulation of antibiotic ciprofloxacin, for the treatment of pediatric patients with acute otitis media with tympanostomy tubes (AOMT). Read More
Cyclenium Pharma Inc., of Sherbrooke, Quebec, and Vienna-based Haplogen GmbH signed a research agreement aimed at the discovery of pharmaceutical candidates in multiple disease areas through a pairing of the companies' drug discovery platforms. Read More
Aveo Oncology Inc., of Cambridge, Mass., filed a registration statement to raise up to $100 million through the sale of securities for general corporate purposes. Shares of Aveo (NASDAQ:AVEO) closed Thursday at $1.36, down 22 cents. Read More
In a decision that gives at least some merit to Amgen Inc.'s interpretation of the patent dance laid out in the Biologic Price Competition and Innovation Act (BPCIA), the Federal Circuit this week granted the innovator biologics maker an injunction preventing, for the time being, the launch of the first FDA-approved biosimilar. Read More
LONDON – San Francisco-based Verseon Corp. has reversed the natural order and chosen the London Stock Exchange for its IPO, raising £65.8 million (US$100 million) in a placing of 36.6 million new shares. Read More
HONG KONG – South Korean drugmaker Celltrion Inc. has received marketing approval for its star product, Remsima, an infliximab biosimilar, in Brazil and Venezuela, marking the beginning of the company's expansion into Latin America. Read More
A new experimental phosphate binder advanced by privately held Phosphate Therapeutics Ltd. to best existing treatments in moderating outsize serum phosphate levels for patients with dialysis-dependent chronic kidney disease appeared safe and effective in a pivotal phase IIb study. Read More
Spyryx Biosciences Inc. is "quickly going from virtual to nonvirtual" with $18 million of series A money in hand, CEO John Taylor told BioWorld Today, and aims to move a therapeutic respiratory compound into the clinic as soon as possible. Read More
Understanding how genomic variation plays out at the level of gene expression in different tissues is a fundamental scientific question, but also a prerequisite for truly harnessing genomic information for therapeutic purposes. Read More
At this week's Allicense 2015 meeting in San Francisco, Jon Norris, managing director of the health care practice at Silicon Valley Bank, described the current biotech financing environment as "a frothy market, but a healthy frothy market." Read More
